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This article presents a rare case of acute toxic hepatitis in thirty-one-year old primigravida. In the 36th 
week of gestation, the patient was introduced nitrofurantoin 100 mg a day due to symptoms of dysuria and 
enterococcus isolated from urine culture. After induced delivery at term because of hypertension, repeated 
laboratory fi ndings showed increased aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) and negative hepatitis C and B markers. The patient was subicteric at the time. Coagulation and 
complete blood count values were within the normal range. Nitrofurantoin therapy was discontinued. 
Abdominal ultrasound was normal with the exception of a slight hepatomegaly without any lesions, focal 
or diffuse. Given that discontinuation of nitrofurantoin and introduction of methylprednisolon therapy 
signifi cantly lowered liver enzyme levels, restoring most of them to normal, we concluded that this was 
probably the case of toxic liver damage caused by nitrofurantoin.
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Nitrofurantoin (NF) is a synthetic antibiotic which 
belongs to the nitrofuran group with nitrofurazon. 
It inhibits numerous bacterial enzymes involved in 
DNA and RNA synthesis, as well as carbohydrate 
metabolism and other metabolic pathways. It 
is clinically useful against a wide spectrum of 
gram-positive (Staphylococcus, Streptococcus, 
Enterococcus) and gram-negative (E. coli, Serratia 
sp., Enterobacter, Klebsiella and Citrobacter) 
bacteria. As such, NF is used widely in treatment and 
prophylaxis of recurrent urinary tract infections in 
pregnancy and in general gynaecology (1).
Different xenobiotics, including drugs, may cause 
liver damage that usually resembles either acute 
hepatitis, cholestatic liver disease or mixed hepatitis 
and cholestasis. However, drug-induced liver injury 
can mimic all forms of acute and chronic hepatobiliary 
diseases (2).
It has become customary to divide liver diseases in 
pregnancy into those which coincide with pregnancy 
and chronic liver disease preceding pregnancy. Toxic 
drug-induced hepatitis in pregnancy belongs to the 
first category. On the other hand, there are liver 
changes induced by pregnancy, which disappear after 
delivery such as hepatocellular damage caused by 
severe preeclampsia, eclampsia, and/or the HELLP 
syndrome (from: Hemolysis, Elevated Liver and a 
Low Platelet).
This article presents a rare case of acute toxic 
hepatitis in pregnancy. After excluding all other factors, 
we narrowed its cause down to nitrofurantoin.
Case presentation
Thirty one-year old primigravida was admitted to 
the pregnancy ward in the 38th week of gestation for 
check up and pregnancy termination. Termination 
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was indicated due to elevated blood pressure 
(140/95 mm Hg to 160/100 mm Hg) without 
proteinuria or oedema. On admittance, the patient 
had irregular contractions and was dilated 4 cm to 
5 cm. Ultrasound check up showed foetus presentating 
head fi rst, with normal biophysical profi le, and normal 
Doppler sonography of the foetal and maternal 
circulation. Anamnesis showed allergy to penicillin 
and family history of hypertonia. During the second 
trimester of pregnancy, the patient was treated with 
cefalexin 2x1.0 g due to E. coli isolated from urine 
culture. From the 34th week of gestation onward she 
was taking atenolol 1x25 mg prescribed by primary 
care gynaecologist to treat slightly elevated blood 
pressure. However, blood pressure was never above 
150/95 mm Hg. Coagulation, liver function, complete 
blood count (CBC), electrolytes, creatinine, and 
blood uric acid were all within normal ranges during 
pregnancy. Repeated urine culture was sterile as 
well. In the 36th week of gestation, the patient started 
to receive daily doses of 1x100 mg of nitrofurantoin 
(Belupo, Croatia) due to symptoms of dysuria and 
enterococcus isolated from urine culture. Excipients 
were as follows: maize starch, talc, magnesium 
stearate, carmellose sodium, titanium dioxide (E171), 
tartrazine (E102), indigo carmine (E132), and gelatine. 
The patient was taking nitrofurantoin for 10 days.
After admittance to the hospital, laboratory tests 
showed elevated liver enzymes with normal CBC 
and coagulogram, without haemolysis (Table 1). 
Also, no jaundice or itching was detected. Because 
of the elevated blood pressure (150/100 mm Hg), 
elevated liver enzymes, 37 weeks of gestation, and 
favourable genital fi nding, delivery was induced with 
amniotomy and oxytocin infusion (Novartis Pharma 
Stein AG, Switzerland), 5 IU of oxytocin in 500 mL 
physiological saline at 30 mL h-1. A live, eutrophic 
male child weighing 2880 g and 48 cm long, was 
delivered with Apgar score 10/10. Manual exploration 
of the uterus was performed to remove remaining 
placenta and the patient was intravenously receiving 
anaesthetics alfentanil (Janssen Pharmaceutica NV, 
Belgium), 1x1 mg and propofol 1 % (Fresenius Kabi 
Austria GmbH, Austria), 1x200 mg. The patient 
received amoxicillin 1x1.2 mg iv, (Pliva Hrvatska, 
Croatia) as prophylaxis. Repeated laboratory fi ndings 
the following day showed increased AST and ALT 
values, negative hepatitis C and B markers, and 
subicterus. NF therapy was discontinued.
Since we identifi ed several signs of liver failure 
such as permanent elevation of liver enzymes and 
subicterus, the patient was transferred to the intensive 
care unit. There she was repeatedly tested for liver 
enzymes. Coagulation and CBC were within the 
Table 1 Results of blood analysis after patient’s admittance to hospital




17:00 h 21:00 h
platelets x 109 / L-1 209 206 195 352 150 to 350
D-dimer / µg L-1 253 313 284 50 to 228
AST / U L-1 420 434 846 73 36 11 to 38
ALT / U L-1 861 940 1425 551 241 12 to 44
LDH / U L-1 665 231 0 to 240
gamma-GT / U L-1 45 57 11 to 53
alkaline phosphatase / U L-1 273 153 45 to 127
glucose / mmol L-1 5.2 3.8 to 6.0
urea / mmol L-1 5.4 3.0 to 8.0
creatinine / µmol L-1 87 75 to 125
uric acid / µmol L-1 347 423 263 140 to 420
total bilirubin / mmol L-1 20.8 10.4 3.0 to 17.0
direct bilirubin / mmol L-1 8.0 2.4 0.0 to 3.4
sodium / mmol L-1 134 135 to 150
potassium / mmol L-1 4.2 3.8 to 5.2
chloride / mmol L-1 103 95 to 105
AST: aspartate aminotranspherase; ALT: alanine aminotranspherase; LDH: lactate dehydrogenase; gamma-GT: gamma-
glutamyl transpeptidase
Bolded values are out of the normal range
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normal range. Abdominal ultrasound was normal 
with the exception of a slight hepatomegaly without 
any lesions, focal or diffuse. Methylprednisolone 
(Pharmacia Upjohn, USA) therapy, 80 mg per day was 
introduced with crystalloid, colloid, and 5 % glucose 
infusions. Given that discontinuation of NF and the 
above mentioned therapy signifi cantly lowered liver 
enzyme levels, restoring most of them to normal, we 
concluded that this was probably the case of toxic liver 
damage caused by NF. With improved liver function, 
the patient was transferred back to the obstetrics and 
gynaecology ward (Table 1).
The course of postpartum period was normal, and 
the patient was discharged with normal blood pressure. 
However, a regular check up with a hepatologist was 
strongly recommended.
DISCUSSION
Being a member of a nitroaryl drug group, 
nitrofurantoin is a lipophilic xenobiotic. Consequently, 
it is readily metabolised by cytochrome P450 
before elimination. One of the enzymes involved 
in nitroaryl reduction is NADPH-cytochrome P450 
reductase localised mainly in the hepatic endoplasmic 
reticulum. Oxidation and reduction of nitroaryls 
depend on the NADPH conditions under which this 
oxidative system catalyses both enzymatic reactions. 
Therefore, oxidative and reductive pathways may 
occur as competitive and simultaneous processes, and 
the toxicity of lipophilic nitroaryls associated with 
oxidative stress may be a consequence of relative 
contributions from both metabolic pathways (3).
Nitrofurantoin is effective in eliminating both 
Gram-negative and Gram-positive pathogens from 
the urinary tract. Rapid absorption and excretion by 
kidneys gives NF its therapeutic value as a urinary 
antibacterial drug. Its half life ranges from 20 min to 
1 h (3). The risk of adverse reactions to NF increases 
with age, and is more common in women than in 
men (89 % vs. 11 %) (4). In patients with normal 
renal function, systemic accumulation of the drug is 
scarce. However, patients with creatinine clearance of 
35 mL min-1 to 40 mL min-1 or a clinically signifi cant 
elevation of serum creatinine should not receive NF 
(5). For this reason, patients receiving long-term NF 
therapy are routinely monitored for changes in renal 
function (6).
NF crosses the placental barrier and can cause 
haemolytic anaemia of the foetus due to its immature 
erythrocyte enzyme system (7).
The most common adverse events associated 
with NF include nausea, headache, and fl atulence 
(4). Although rare, serious adverse events in 
patients receiving long-term (>6 months), low-dose 
NF prophylaxis have also been reported. These 
include chronic pulmonary reactions, hepatic injury, 
peripheral neuropathy, and hypersensitivity to NF 
(4, 8-12). Here we report the case of acute liver 
damage caused by administration of NF. Previous 
studies indicate that hepatotoxicity is the most lethal 
NF-related adverse reaction (8-12). NF probably 
produces massive oxidative stress in hepatocytes, 
due to the nitroreductive metabolism of the drug 
(13). However, cases have been reported of immune-
mediated liver injury (14, 15). This supported by 
lupus erythematosus-like presentation, autoantibodies 
against nuclear antigen and smooth muscle, and by 
hypergammaglobulinaemia. In general, determining 
the cause of hepatic toxicity is complex because this 
requires liver biopsy and drug rechallenge.
Our patient was taking NF for ten days. This may 
be too short a period for a hepatotoxic reaction to 
develop. She had normal creatinine clearance; there 
were no signs of haemolytic anaemia in either the 
mother or the child, and the mother’s liver enzyme 
levels declined after discontinuation of NF. We 
can conclude that NF was responsible for acute 
liver damage either by direct action or as a result of 
pregnancy-related metabolic changes. Considering the 
incidence of liver damage in the HELPP syndrome 
or preeclampsia and/or eclampsia, assessment of 
the liver function and patient’s general condition is 
strongly recommended before administering NF to 
pregnant women.
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Sažetak
AKUTNO OŠTEĆENJE JETRE UZROKOVANO PRIMJENOM NITROFURANTOINA U 
TRUDNOĆI
Autori prikazuju rijedak slučaj akutnog oštećenja jetre - akutni toksični hepatitis u 31-godišnje primigravide. 
U 36. tjednu trudnoće zbog dizuričnih smetnji i dokazanog enterokoka u urinokulturi ordiniran je 
nitrofurantoin 1x100 mg. Nakon terminski induciranoga poroda zbog hipertenzije, ponovljene laboratorijske 
pretrage upućuju na značajno povišenje vrijednosti jetrenih enzima uz negativne markere na C i B-hepatitis 
te subikterus. Koagulogram i crvena krvna slika bili su uredni. Nitrofurantoin se isključuje iz terapije. 
Abdominalni ultrazvuk upućuje na hepatomegaliju bez fokalnih ili difuznih oštećenja.
Nakon isključenja nitrofurantoina iz terapije uz metilprednizolon, vrijednosti jetrenih enzima se 
normaliziraju, što potvrđuje slučaj toksičnog oštećenja jetre uzrokovanog nitrofurantoinom.
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